| [1] |
Dilinuer TAXIMAIMAITI, Palida ABULIZI.
Efficacy and safety of abrocitinib and dupilumab in the treatment of moderate to severe atopic dermatitis
[J]. China Journal of Leprosy and Skin Diseases, 2024, 40(8): 533-537.
|
| [2] |
GUO Shuting, LI Ruijie, YANG Meili, JIN Yaqiao, ZHAO Yiyu, ZHANG Lu, HAN Hui, HAO Yong.
Effect of dupilumab on Staphylococcus aureus colonization in adults with moderate to severe atopic dermatitis
[J]. China Journal of Leprosy and Skin Diseases, 2024, 40(8): 545-549.
|
| [3] |
CHEN Liuxin, CAI Yanxia, LIU Yaqin, YANG Yanping, XIE Yingxia, DENG Shiyin, LUO Yaqi.
Bullous scabies: 3 cases report and literature review
[J]. China Journal of Leprosy and Skin Diseases, 2024, 40(7): 474-479.
|
| [4] |
ZHENG Chunzhi, ZHANG Minkuo, SAI Wenwen, CAO Yuanyuan, ZHANG Zhaoxia, PAN Futang, YANG Baoqi, LIU Hong.
Bullous pemphigoid occurred after long-term treatment with camrelizumab in a patient with oesophageal cancer: a case report
[J]. China Journal of Leprosy and Skin Diseases, 2024, 40(6): 422-424.
|
| [5] |
WU Qian, JIANG Fuqiong, YOU Shuqiong, WANG Yuan, WU Yongzhuo.
Update of the treatment of bullous pemphigoid based on disease-modifying
[J]. China Journal of Leprosy and Skin Diseases, 2024, 40(5): 371-376.
|
| [6] |
XU Yuanyuan, GUO Linghong, WU Shuwei, ZHANG Ting, ZHANG Lu, JIANG Xian.
Causal associations between three atopic diseases and alopecia areata: a two-sample Mendelian randomization study
[J]. China Journal of Leprosy and Skin Diseases, 2024, 40(4): 239-244.
|
| [7] |
DONG Feifan, LIU Yongxia, TIAN Hongqing.
Bullous pemphigoid with erosions and ulceras on genital as the first symptom: a case report and literature review
[J]. China Journal of Leprosy and Skin Diseases, 2024, 40(4): 255-258.
|
| [8] |
CHEN Xueqin, SONG Zhiqiang.
Update of skin tissue-resident memory T cells and inflammatory skin diseases recurrence
[J]. China Journal of Leprosy and Skin Diseases, 2024, 40(4): 292-296.
|
| [9] |
HAN Junya, WU Weiwei, HE Xiaojun, ZHU Wenwen, FANG Xianfeng.
Related factors analysis and prediction model establishment of malignant tumor in patients with bullous pemphigoid
[J]. China Journal of Leprosy and Skin Diseases, 2024, 40(3): 157-162.
|
| [10] |
HAN Jinghong, LIU Hong.
Two children with refractory atopic dermatitis successfully treated with Janus kinase inhibitors
[J]. China Journal of Leprosy and Skin Diseases, 2024, 40(3): 190-192.
|
| [11] |
CHANG Jiayu, QI Miao, WANG Yimin, LI Yongxi, SHI Tongxin.
Bullous pemphigoid occurred in a patient with severe plaque psoriasis treated with secukinumab: a case report
[J]. China Journal of Leprosy and Skin Diseases, 2024, 40(3): 199-201.
|
| [12] |
HUANG Gerile, ZHANG Wenjing, YANG Hongxin, GUO Hao.
Efficacy and safety of Janus kinase inhibitors for moderate-to-severe atopic dermatitis: a network meta-analysis
[J]. China Journal of Leprosy and Skin Diseases, 2024, 40(10): 690-698.
|
| [13] |
ZHANG Ruixia, TANG Junting, HE Angran.
Glucocorticoid combined with dupilumab in the treatment of bullous pemphigoid complicated with verruca plana: a case report
[J]. China Journal of Leprosy and Skin Diseases, 2024, 40(10): 727-729.
|
| [14] |
ZHOU Yuxi, LI Jishu, WANG Jinqiu, LI Xiaohong, FENG Chenchen, ZHOU Xingli, LI Wei.
Efficacy and safety of dupilumab in the treatment of bullous pemphigoid for 16 weeks: a retrospective study
[J]. China Journal of Leprosy and Skin Diseases, 2024, 40(1): 21-25.
|
| [15] |
ZHOU Xiaonan, CAO Chunyan, SHI Yaping, QI Maoxuan, ZHANG Qianying, ZONG Yan.
Latent profile analysis of family management characteristics in children with atopic dermatitis
[J]. China Journal of Leprosy and Skin Diseases, 2024, 40(1): 39-44.
|
